To appear in Best of the Brokers, email your research to email@example.com
Jefferies reiterated the biopharmaceutical giant’s “buy” rating, following solid results for the final quarter of 2014, and an initial 2015 outlook in line with the broker’s expectations. Jefferies also said it foresees “numerous pipeline catalysts this year to drive potential earnings upgrades”.
Numis reiterated its “buy” rating on the digital media company ahead of the release of the firm’s final results next week. The broker stated that the group “continues to make good progress across its digital and production businesses”, and maintained target price at 481p.
Cantor Fitzgerald reiterated its “buy” rating on the manufacturing firm, and stated that the first look at its results “appears encouraging”, but added that “the company is clearly concerned about economic conditions, notably in oil and gas or marine.” Target price is maintained at 1,310p.